Peptide record

TPDB64709

HAVN2 Blood-Brain Barrier standard
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB64709
HAVN2
Blood-Brain Barrier
Delivery and barrier-penetrating peptides
B3Pred BBPpredict Peptipedia
standard
No
A 5-aa standard-residue blood-brain barrier peptide sequence curated from B3Pred, BBPpredict, and Peptipedia, with an available 3D structural model.
Sequence
SHAVS
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C20H33N7O8
RNDCEQGILKMFPTWY
S
499.52
7.85
1
0
2
+0
1.12
0.240
78.00
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
0
I
0
L
0
K
0
M
0
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
5 reviewed residue count
C20H33N7O8 sequence-only estimate (linear, free termini)
499.52 sequence-only estimate (linear, free termini)
7.85 sequence-only estimate (linear, free termini)
+0 sequence-only estimate (linear, free termini)
1.12 sequence-only estimate (linear, free termini)
0.240 sequence-only estimate (linear, free termini)
Cyclic Activity
SerHisAlaValSer Activity
N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)O Activity
Evidence Records 1 records
Evidence 1 Activity

Activity

Blood-Brain Barrier

Assay & Model

Mass Spectromtery
It is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain.

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intracerebral ventricular
Synthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA
Combined with monoclonal antibody
Additional Detail Fields 1 fields
Intracerebral ventricular